Carbon nanoparticles developed as potential MRI contrast agents

Researchers at CIC biomaGUNE, led by Professor Maurizio Prato and Lucia Cardo, have developed manganese-doped carbon nanoparticles that may serve as a next-generation contrast agent for Magnetic Resonance Imaging (MRI).

Published in ACS Nano, the study demonstrates that spherical carbon nanoparticles, approximately five nanometers in size, provide contrast comparable to or in some cases superior to current commercial agents. This research seeks to provide a safer and more affordable alternative to gadolinium, which has been the diagnostic standard for nearly four decades but poses risks to patients with renal failure and contributes to environmental pollution.

Animal model testing indicated high biocompatibility and rapid elimination from the organism, with no significant toxic effects observed in major organs. The nanoparticles also possess fluorescent properties, allowing for potential multi-modal imaging. While the platform is stable and reproducible, the technology must still undergo extensive human clinical trials before it can be used in medical practice.